#pharmaceutical-manufacturing

#pharmaceutical-manufacturing

President Trump said the administration has reached agreements with nine more drugmakers to bring their U.S. drug prices more in line with what other wealthy countries pay. Fourteen companies in total have now reached what the administration calls most-favored-nation pricing deals. The companies that took part in Friday's announcement were: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi. They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries.

This coming Thursday is Thanksgiving. It seems both far too soon and yet forever since our last turkey day. We have all been through hell and back since the last time we gathered around the table with friends and family to give thanks while trying to restrain the urge to throttle that relative who is a pain in the ass every holiday.

Juzen Chemical Corporation, founded in 1950 in Toyama City, is a contract manufacturer of active pharmaceutical ingredients. Situated between the Jintsu River and the Fugan Canal within an industrial park, the company decided to consolidate its dispersed offices, meeting rooms, and cafeteria into a new headquarters. The new building not only addresses operational efficiency but also reflects Toyama's natural environment and cultural heritage, while offering a workplace that enhances employee well-being and connects with the surrounding community.

Sun Pharma's factory faced severe scrutiny after inspectors found contamination, leading to a ban on exportation to the U.S., highlighting the conflict between safety and drug supply.